Search Result

Results for "

HDAC2-IN-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (18) Autophagy (3) Bcl-2 Family (2) Caspase (1) CDK (3) Gli (1) HDAC (41) Hedgehog (1) Histone Demethylase (2) iGluR (1) Parasite (3) Phosphodiesterase (PDE) (1) PI3K (2) PROTACs (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Sirtuin (1) Topoisomerase (2)
By Research Areas:	Cancer (33) Cardiovascular Disease (1) Infection (4) Neurological Disease (5)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13522

Fimepinostat 10+ Cited Publications CUDC-907	PI3K HDAC Apoptosis	Cancer
Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II *HDAC* enzymes with an IC₅₀ of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

HY-12164

Mocetinostat Maximum Cited Publications 22 Publications Verification MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for *HDAC1, HDAC2, HDAC3* and *HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC*8.

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-111400

SR-4370	HDAC	Cancer
SR-4370 is an inhibitor of *HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3* μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

HY-18613

CAY10603 5+ Cited Publications BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-W105310A

Croconic acid disodium Nacr	HDAC Sirtuin CDK Bcl-2 Family Apoptosis	Others
Croconic acid disodium (Nacr) is a lysine crotonylation (Kcr) activator and electroactive material. Croconic acid disodium reduces the expression of *HDAC2, HDAC3*, SIRT1, and SIRT3, and increases the expression of EP300, CITED1, ACSS2, DPF2, CDYL, MLLT3, and YEATS2. Croconic acid disodium elevates intracellular crotonyl-CoA content and global histone lysine crotonylation levels. Croconic acid disodium promotes the growth of bovine fibroblasts, regulates cell cycle progression, and inhibits bovine fibroblast apoptosis (apoptosis). Croconic acid disodium improves the blastocyst development efficiency of bovine somatic cell nuclear transfer embryos. Croconic acid disodium undergoes reversible lithium intercalation/deintercalation reactions via sodium-lithium ion exchange. Croconic acid disodium is applicable to research related to cell growth promotion .

HY-19754A

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum *HDAC* (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3*, *HDAC6, HDAC8, and HDAC10* are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116818

Crebinostat	HDAC	Neurological Disease
Crebinostat is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.7 nM, 1.0 nM, 2.0 nM and 9.3 nM for HDAC1, HDAC2, HDAC3 and HDAC6, respectively. Crebinostat potently induces acetylation of both histone H3 and histone H4 as well as enhances the expression of the cAMP response element-binding protein (CREB) target gene Egr1. Crebinostat increases the density of synapsin-1 punctae along dendrites in cultured neurons. Crebinostat can modulate chromatin-mediated neuroplasticity and exhibits enhanced memory in mice .

HY-131708A

FNDR-20123	HDAC Parasite	Infection
FNDR-20123 is a safe, first-in-class, and orally active anti-malarial *HDAC* inhibitor with IC₅₀s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC₅₀=41 nM) and sexual blood stage (IC₅₀=190 nM for male gametocytes). FNDR-20123 inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC₅₀=25/29/2/11/282 nM, respectively.) and inhibits Class III HDAC isoforms at nanomolar concentrations .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3*, and *HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

HY-110280

MC1742	HDAC Apoptosis	Cancer
MC1742 is a potent *HDAC* inhibitor, with IC₅₀s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-182321

*HDAC2-IN-3*	HDAC	Neurological Disease
HDAC2-IN-3 is a selective, orally active, blood-brain barrier permeable *HDAC2* inhibitor with an IC₅₀ of 14 nM. HDAC2-IN-3 upregulates histone acetylation levels in cells and in vivo, and enhances long-term potentiation (LTP) in the hippocampus. HDAC2-IN-3 can be used for the research of Alzheimer's disease .

HY-10221G

Vorinostat (GMP) SAHA (GMP); Suberoylanilide hydroxamic acid (GMP)	HDAC	Infection Cancer
Vorinostat (GMP) is a GMP grade Vorinosta (HY-10221). GMP-grade small molecules can be used as auxiliary agents in cell therapy. Vorinostat is a potent, orally available **HDAC1, HDAC2, HDAC3 (Class I), HDAC6 and Inhibitors of HDAC7 (Class II)** and Class IV (HDAC11) .

HY-149029

TH-6	HDAC Apoptosis Reactive Oxygen Species (ROS)	Cancer
TH-6 is a potent *HDAC* inhibitor with IC₅₀s of 0.115, 0.135, 0.242, 0.138, 2.120 µM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively. TH-6 inhibits cell migration and invasion. TH-6 induces apoptosis and cell cycle arrest at G2/M phase. TH-6 shows anti-tumor activity .

HY-144293

HDAC-IN-31	Apoptosis HDAC	Cancer
HDAC-IN-31 is a potent, selective and orally active *HDAC* inhibitor with IC₅₀s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma .

HY-146276

*CDK/HDAC-IN-2*	HDAC CDK Apoptosis	Cancer
CDK/HDAC-IN-2 is a potent *HDAC/CDK* dual inhibitor with IC₅₀ of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy .

HY-173064

DS-103	HDAC Parasite	Infection Cancer
DS-103 is an inhibitor for *HDAC* that inhibits *HDAC1, HDAC2, HDAC3*, *HDAC6* and *HDAC8* with IC₅₀s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC₅₀ of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC₅₀ of 1.48 μM and 1.47 μM, reverses Cisplatin (HY-17394) resistance in A2780 and Cal27 with IC₅₀ of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis .

HY-175671

*LSD1/HDAC-IN-3*	HDAC Histone Demethylase	Neurological Disease
LSD1/HDAC-IN-3 is a inhibitor targeting class I *HDAC* and LSD1 enzymes. LSD1/HDAC-IN-3 inhibits *HDAC1, HDAC2, HDAC3*, and LSD1 with IC₅₀ values of 1702 nM, 842 nM, 358 nM, and 1074 nM, respectively. LSD1/HDAC-IN-3 exhibits antioxidant effects in H2O2-stressed ARPE-19 and 661W retinal cells, increasing levels of acetylated and methylated histone H3. LSD1/HDAC-IN-3 enhances photoreceptor survival in the rd10 mouse model of retinitis pigmentosa. LSD1/HDAC-IN-3 can be used for the study of inherited retinal diseases such as retinitis pigmentosa (RP) .

HY-151896

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HY-155890

Fimepinostat mesylate CUDC-907 mesylate	PI3K HDAC Apoptosis	Cancer
Fimepinostat mesylate potently inhibits class I PI3Ks as well as classes I and II *HDAC* enzymes with an IC₅₀ of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

HY-112908

RTS-V5	HDAC Proteasome	Cancer
RTS-V5 is a dual *HDAC/proteasome* inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

HY-119316A

CM-545	HDAC Phosphodiesterase (PDE)	Neurological Disease
CM-545, the cis-isomer of CM-414 (HY-119316), is a dual inhibitor of PDE5, *HDAC1, HDAC2, HDAC3*, and *HDAC6* with pIC₅₀ values of 7.47, 6.65, 6.14, 6.55, and 6.84, repectively .

HY-163430

HDAC-IN-71	HDAC Apoptosis	Cancer
HDAC-IN-71 (Compound 17q) is a potent *HDAC* inhibitor with IC₅₀ values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research .

HY-12487

NL-103	HDAC Hedgehog Gli	Cancer
NL-103 is an inhibitor of histone deacetylases (HDACs) and Hedgehog, with the IC₅₀ values of 21.3 nM, 57 nM, 74 nM, and 680 nM for *HDAC1, HDAC2, HDAC3*, and *HDAC6, respectively. NL-103 can downregulate the expression of Gli2*. NL-103 can be used in anti-cancer research .

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .

HY-147873

*NMDAR/HDAC-IN-1*	iGluR HDAC	Neurological Disease
NMDAR/HDAC-IN-1 (Compound 9d) is a dual NMDAR and *HDAC* inhibitor with a K_i of 0.59 μM for NMDAR and IC₅₀ values of 2.67, 8.00, 2.21, 0.18 and 0.62 μM for HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8, respectively. NMDAR/HDAC-IN-1 efficiently penetrates the blood brain barrier .

HY-170379

HDAC-IN-84	HDAC Apoptosis	Cancer
HDAC-IN-84 (compound 4d) is a potent *HDAC* inhibitor, with IC₅₀ values of 0.0045, 0.015, 0.013, 0.038, 5.8 and 26 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC11, respectively. HDAC-IN-84 effectively inhibits the proliferation of leukemia cells without causing toxicity .

HY-18613R

CAY10603 (Standard) BML-281 (Standard)	HDAC Reference Standards	Cancer
CAY10603 (Standard) is the analytical standard of CAY10603. This product is intended for research and analytical applications. CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor, with an IC50 of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC50s of 271, 252, 0.42, 6851, 90.7 nM.

HY-152173

HDAC-IN-51	HDAC Apoptosis Bcl-2 Family CDK	Cancer
HDAC-IN-51 is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.32, 0.353, 0.431, 0.515, and 85.4 μM for HDAC10, HDAC1, HDAC2, HDAC3 and HDAC11, respectively. HDAC-IN-51 induces cell cycle arrest and apoptosis, modulating cell cycle-/apoptosis-related miRNAs expression. HDAC-IN-51 can be used in research of cancer .

HY-12164R

Mocetinostat (Standard) MGCD0103 (Standard)	HDAC Autophagy Apoptosis Reference Standards	Cancer
Mocetinostat (Standard) is the analytical standard of Mocetinostat. This product is intended for research and analytical applications. Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.

HY-144654

HDAC/Top-IN-1	HDAC Topoisomerase	Cancer
HDAC/Top-IN-1 is an orally active and pan *HDAC/Top* dual inhibitor with IC₅₀s of 0.036 μM, 0.14 μM, 0.059 μM, 0.089 μM and 9.8 μM for *HDAC1, HDAC2, HDAC3*, *HDAC6* and *HDAC8. HDAC/Top-IN-1 efficiently induces apoptosis* with S cell-cycle arrest in HEL cells. HDAC/Top-IN-1 has exhibits excellent in vivo antitumor efficacy .

HY-145851

*Top/HDAC-IN-1*	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a *topoisomerase/HDAC* dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells .

HY-19754

CRA-026440	HDAC Apoptosis	Cardiovascular Disease Cancer
CRA-026440 is a potent, broad-spectrum *HDAC* inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3*, *HDAC6, HDAC8, and HDAC10* are 4, 14, 11, 15, 7, and 20 nM respectively. CRA-026440 shows antitumor and antiangiogenic activities . CRA-026440 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163834

HDAC6-IN-47	HDAC	Cancer
HDAC6-IN-47 (Compound S-29b) is inhibitor for *HDAC, which exhibits high affinities to HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 with K_i* of 60, 56, 162, 0.44, 362 and 849 nM, respectively. HDAC6-IN-47 causes tubulin hyperacetylation in MV4-11, inhibits the proliferation of MV4-11 with an EC₅₀ of 0.50 µM. HDAC6-IN-47 can be used in research of leukemia .

HY-154855

HDAC-IN-56	HDAC	Cancer
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC₅₀ values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .

HY-172359

*PROTAC HDAC6 degrader 4*	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 4 (Compound 17c) is the PROTAC degrader for *HDAC6* with a DC₅₀ of 14 nM. PROTAC HDAC6 degrader 4 exhibits inhibitory activit against *HDAC1, HDAC2, HDAC3* and *HDAC6* with IC₅₀s of 2.2, 2.37, 0.61 and 0.295 μM, respectively . (Pink: ligand for target protein HDAC6 ligand-3 (HY-172360); Black: linker (HY-138387); Blue: ligand for cereblon E3 ligase (HY-W093272))

HY-131708

FNDR-20123 free base	HDAC Parasite	Infection
FNDR-20123 free base is a safe, first-in-class, and orally active anti-malarial *HDAC* inhibitor with IC₅₀s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 free base exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC₅₀=41 nM) and sexual blood stage (IC₅₀=190 nM for male gametocytes). FNDR-20123 free base inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC₅₀=25, 29, 2, 11, and 282 nM, respectively) and inhibits Class III HDAC isoforms at nanomolar concentrations .

HY-169938

*LSD1/HDAC-IN-2*	HDAC Histone Demethylase Apoptosis	Cancer
LSD1/HDAC-IN-2 (Compound 20c) is the inhibitor for LSD and *HDAC, that inhibits LSD1, HDAC1, HDAC2, HDAC3*, *HDAC6, and HDAC8, with IC₅₀s of 39.0, 1.4, 1.0, 1.3, 2.9 and 16.0 nM, respectively. LSD1/HDAC-IN-2 inhibits the proliferation of cancer cells, especially the colorectal cancer cells. LSD1/HDAC-IN-2 arrests the cell cycle at G2/M phase, inhibits cell migration, and induces apoptosis* in HCT-116 and HT-29 cells. LSD1/HDAC-IN-2 exhibits antitumor efficacy in mouse model without significant toxicity .

HY-183150

HDAC1-IN-13	HDAC Apoptosis Caspase	Cancer
HDAC1-IN-13 is an orally active HDAC1 inhibitor with IC₅₀ values of 91, 185, 170, and 280 nM against *HDAC1, HDAC2, HDAC3*, and *HDAC10, respectively, and shows no activity against HDAC4, HDAC5, HDAC6, HDAC7, and HDAC9. HDAC1-IN-13 induces extrinsic apoptosis* by activating the caspase-8 pathway and triggers G0/G1 cell cycle arrest. HDAC1-IN-13 can be used for the research of leukemia .

HY-181009

HDAC-IN-98	HDAC Apoptosis Autophagy	Cancer
HDAC-IN-98 is a *HDAC1, HDAC2, HDAC3* inhibitor (one of the most selective class I *HDAC* inhibitors) with human IC₅₀ values of 41.2 nM, 52.5 nM, and 74.3 nM respectively. HDAC-IN-98 induces H3K9 acetylation, p21 upregulation, G2/M arrest, cell apoptosis, has strong antiproliferative effects in colorectal cancer cells, low toxicity in healthy colon epithelium, modulates short-term in vitro effects via autophagy, and shows strong antitumor efficacy in vivo in the chorioallantoic membrane model (CAM) assay. HDAC-IN-98 can be used for the research of colorectal cancer .

Vorinostat (GMP) SAHA (GMP); Suberoylanilide hydroxamic acid (GMP)	Fluorescent Dye
Vorinostat (GMP) is a GMP grade Vorinosta (HY-10221). GMP-grade small molecules can be used as auxiliary agents in cell therapy. Vorinostat is a potent, orally available **HDAC1, HDAC2, HDAC3 (Class I), HDAC6 and Inhibitors of HDAC7 (Class II)** and Class IV (HDAC11) .

Vorinostat (GMP) SAHA (GMP); Suberoylanilide hydroxamic acid (GMP)	Biochemical Assay Reagents
Vorinostat (GMP) is a GMP grade Vorinosta (HY-10221). GMP-grade small molecules can be used as auxiliary agents in cell therapy. Vorinostat is a potent, orally available **HDAC1, HDAC2, HDAC3 (Class I), HDAC6 and Inhibitors of HDAC7 (Class II)** and Class IV (HDAC11) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: